Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Catabasis Pharmaceuticals, Inc (NASDAQ: CATB).

Full DD Report for CATB

You must become a subscriber to view this report.


Recent News from (NASDAQ: CATB)

Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q1 2018 Results - Earnings Call Transcript
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Q1 2018 Earnings Conference Call May 10, 2018 8:30 AM ET Executives Andrea Matthews - Vice President of Corporate Affairs Jill Milne - Co-Founder and Chief Executive Officer Joanne Donovan - Chief Medical Officer and Senior Vice Pr...
Source: SeekingAlpha
Date: May, 10 2018 12:48
Catabasis Pharmaceuticals: Elucidating Edasalonexent's Stellar Prospects In DMD
I would argue that passion is more important than brain power. - Charlie Munger Catabasis Pharmaceuticals (NASDAQ: CATB ) is an interesting bioscience for various reasons. First, the company is brewing a highly enriched pipeline with the lead molecule (edasalonexent) that has the potenti...
Source: SeekingAlpha
Date: May, 10 2018 11:34
Catabasis Pharmaceuticals 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Catabasis Pharmaceuticals in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 10 2018 08:41
Catabasis Pharmaceuticals misses by $0.09
Catabasis Pharmaceuticals (NASDAQ: CATB ): Q1 EPS of -$0.29 misses by $0.09 . More news on: Catabasis Pharmaceuticals, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 08:09
Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress
-- MoveDMD ® Trial Data Through One Year of Treatment Reinforce Edasalonexent Potential as Disease-Modifying Therapy for Duchenne Muscular Dystrophy -- -- 2018 Priorities Focused on Advancing Edasalonexent and Improving the Lives of Boys Affected by Duchenne Muscular Dystroph...
Source: Business Wire
Date: May, 10 2018 08:05
Market Trends Toward New Normal in Church & Dwight Co., Rent-A-Center, Teradata, Catabasis Pharmaceuticals, Tronox, and Callaway Golf - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Church & Dwight Co., Inc. (NYSE:CHD), Rent-A-Center, Inc. (NASDAQ:RCII...
Source: GlobeNewswire
Date: May, 09 2018 08:15
Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10
The Company Will Host a Conference Call at 8:30am ET Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2018 financial results before the NASDAQ Global Market open on Thursday, May 10, 2018. Jill C. Milne, Ph.D., Chie...
Source: Business Wire
Date: May, 03 2018 08:00
Solid Biosciences moving closer to removal of clinical hold on early-stage study of DMD candidate SGT-001; shares up 6%
Thinly traded Solid Biosciences ( SLDB +5.5% ) is up, albeit on turnover of only 85K shares, on its announcement that it has received a letter from FDA concerning the full clinical hold on its Phase 1/2 study of gene therapy SGT-001 in patients with Duchenne muscular dystrophy. The agenc...
Source: SeekingAlpha
Date: April, 30 2018 13:43
Capricor launches mid-stage study of DMD candidate CAP-1002; shares up 2%
Capricor Therapeutics ( CAPR +1.5% ) initiates a Phase 2 clinical trial, HOPE-2 , assessing CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD). More news on: Capricor Therapeutics, Inc., Sarepta Therapeutics, Inc., Catabasis Pharmaceuticals, Healthcare stocks news, ...
Source: SeekingAlpha
Date: April, 30 2018 13:23
Biotech Analysis Central Pharma News: AstraZeneca's Fumble, Acadia's Nuplazid Review, Catabasis' Second Success In DMD
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. AstraZeneca Fumbles In Latest Lung Cancer Data News: Recently, AstraZeneca ( AZN ) announced results from a study in lung cancer patients who has pre...
Source: SeekingAlpha
Date: April, 26 2018 21:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-251.601.581.6111.56120,148
2018-05-241.601.601.611.5793,082
2018-05-231.601.601.621.5858,350
2018-05-221.631.601.641.5954,152
2018-05-211.641.631.651.6158,253

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2524,70067,07336.8255Short
2018-05-2434,52451,52467.0057Short
2018-05-2324,83839,30763.1898Short
2018-05-2211,63536,10432.2263Cover
2018-05-219,86229,22433.7462Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CATB.


About Catabasis Pharmaceuticals, Inc (NASDAQ: CATB)

Logo for Catabasis Pharmaceuticals, Inc (NASDAQ: CATB)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $47,327,868 - 05/11/2018
  • Issue and Outstanding: 29,035,502 - 03/07/2018

 


Recent Filings from (NASDAQ: CATB)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 04 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: CATB)

Daily Technical Chart for (NASDAQ: CATB)


Stay tuned for daily updates and more on (NASDAQ: CATB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CATB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CATB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of CATB and does not buy, sell, or trade any shares of CATB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/